222 related articles for article (PubMed ID: 34053791)
21. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2018-June 2019.
Jorba J; Diop OM; Iber J; Henderson E; Zhao K; Quddus A; Sutter R; Vertefeuille JF; Wenger J; Wassilak SGF; Pallansch MA; Burns CC
MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(45):1024-1028. PubMed ID: 31725706
[TBL] [Abstract][Full Text] [Related]
22. Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.
Diop OM; Burns CC; Sutter RW; Wassilak SG; Kew OM;
MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):640-6. PubMed ID: 26086635
[TBL] [Abstract][Full Text] [Related]
23. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237
[TBL] [Abstract][Full Text] [Related]
24. Notes from the Field: Circulating Vaccine-Derived Poliovirus Outbreaks - Five Countries, 2014-2015.
Morales M; Nnadi CD; Tangermann RH; Wassilak SG
MMWR Morb Mortal Wkly Rep; 2016 Feb; 65(5):128-9. PubMed ID: 26866942
[TBL] [Abstract][Full Text] [Related]
25. Modeling the dynamics of oral poliovirus vaccine cessation.
Thompson KM; Duintjer Tebbens RJ
J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
[TBL] [Abstract][Full Text] [Related]
26. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
[TBL] [Abstract][Full Text] [Related]
27. Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020.
Al-Qassimi MA; Al Amad M; Anam L; Almoayed K; Al-Dar A; Ezzadeen F
BMC Infect Dis; 2022 Apr; 22(1):414. PubMed ID: 35488227
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study.
Cooper LV; Erbeto TB; Danzomo AA; Abdullahi HW; Boateng K; Adamu US; Shuaib F; Modjirom N; Gray EJ; Bandyopadhyay AS; Zipursky S; Okiror SO; Grassly NC; Blake IM
Lancet Infect Dis; 2024 Apr; 24(4):427-436. PubMed ID: 38246190
[TBL] [Abstract][Full Text] [Related]
29. Circulating vaccine-derived polioviruses: current state of knowledge.
Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
[TBL] [Abstract][Full Text] [Related]
30. Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
Molodecky NA; Jafari H; Safdar RM; Ahmed JA; Mahamud A; Bandyopadhyay AS; Shukla H; Quddus A; Zaffran M; Sutter RW; Grassly NC; Blake IM
Vaccine; 2023 Apr; 41 Suppl 1():A93-A104. PubMed ID: 34629206
[TBL] [Abstract][Full Text] [Related]
31. Vaccine-derived poliovirus surveillance in China during 2001-2013: the potential challenge for maintaining polio free status.
Wang HB; Luo HM; Li L; Fan CX; Hao LX; Ma C; Su QR; Yang H; Reilly KH; Wang HQ; Wen N
BMC Infect Dis; 2017 Dec; 17(1):742. PubMed ID: 29197328
[TBL] [Abstract][Full Text] [Related]
32. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
33. Polio outbreak investigation and response in Somalia, 2013.
Kamadjeu R; Mahamud A; Webeck J; Baranyikwa MT; Chatterjee A; Bile YN; Birungi J; Mbaeyi C; Mulugeta A
J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S181-6. PubMed ID: 25316834
[TBL] [Abstract][Full Text] [Related]
34. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
[TBL] [Abstract][Full Text] [Related]
35. Curbing an outbreak of circulating vaccine derived poliovirus type 2 in Dollo Zone, Somali Region, Ethiopia: response to outbreak.
Kidanne L; Bisrat F; Mohammed M; Deyessa N
Pan Afr Med J; 2022; 42():46. PubMed ID: 35949467
[TBL] [Abstract][Full Text] [Related]
36. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
37. Circulating vaccine-derived polioviruses in the Extreme North region of Cameroon.
Endegue-Zanga MC; Sadeuh-Mba SA; Iber J; Burns C; Nimpa-Mengouo M; Demanou M; Vernet G; Etoa FX; Njouom R
J Clin Virol; 2015 Jan; 62():80-3. PubMed ID: 25542478
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of wild polio virus outbreak investigation and response in Ethiopia in 2013-2014: implications for prevention of outbreaks due to importations.
Tegegne AA; Braka F; Shebeshi ME; Aregay AK; Beyene B; Mersha AM; Ademe M; Muhyadin A; Jima D; Wyessa AB
BMC Infect Dis; 2018 Jan; 18(1):9. PubMed ID: 29304745
[TBL] [Abstract][Full Text] [Related]
39. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
[TBL] [Abstract][Full Text] [Related]
40. Outbreaks of Circulating Vaccine-Derived Poliovirus in the World Health Organization Western Pacific Region, 2000-2021.
Kitamura K; Shimizu H
Jpn J Infect Dis; 2022 Sep; 75(5):431-444. PubMed ID: 36047174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
